Retinal therapy pipeline, 2026 mid-year reference

Reference layout of the retinal therapy pipeline as of mid-2026. Includes approved mechanisms across wet AMD, DME, geographic atrophy, and inherited retinal dystrophy, late-stage pipeline by mechanism, and the live commercial questions including delivery innovation, biosimilar dynamics, and gene-therapy progress. The category is in structural transition, and orienting to the landscape is essential for cross-functional teams entering the retinal conversation.